Search
Gallium maltolate
go.drugbank.com/drugs/DB05420InvestigationalGallium maltolate is Titan’s novel oral agent in development for the potential treatment of chronic bacterial infections, bone disease and cancer.
PRO-542
go.drugbank.com/drugs/DB05793InvestigationalPRO 542 belongs to a new class of drugs, viral-entry inhibitor, which is intended to prevent HIV from entering and infecting cells. PRO 542 (CD4-immunoglobulin G2) is a tetravalent CD4-immunoglobulin fusion protein that broadly neutraliz...
Rolofylline
go.drugbank.com/drugs/DB12670InvestigationalRolofylline is under clinical development by pharmaceutical company NovaCardia for the treatment of congestive heart failure.
ARC183
go.drugbank.com/drugs/DB05124ExperimentalThe key advantage of ARC183 compared to other thrombin inhibitors is its rapid onset of action and short half-life, giving it the potential to be an ideal agent for medical procedures that require rapid
1D09C3
go.drugbank.com/drugs/DB05121Experimental1D09C3, a monoclonal antibody against lymphoid cancers, is an anti-MHC (major histocompatibility complex) class II monoclonal antibody.
Bleomycin A6
go.drugbank.com/drugs/DB12992InvestigationalIt was developed in China as an antineoplastic antibiotic. This drug participated in clinical trials for the treatment of Squamous Cell Lung Cancer.
CR002
go.drugbank.com/drugs/DB05139InvestigationalCR002 is a novel investigational fully human monoclonal antibody that blocks the activity of excess platelet-derived growth factor-D (PDGF-D), a target shown to play a role in kidney inflammation.
Synonyms: Human monoclonal antibody against platelet-derived growth factor Dbeta-Hydroxybutyric acid
go.drugbank.com/drugs/DB16506InvestigationalBeta-hydroxybutyrate is being studied in around 230 clinical trials, including NCT06351124 (recruiting for Crohn's disease), NCT05584371 (recruiting for safety and tolerability of exogenous ketosis), NCT04656236 (completed for type 1 dia...
AdPEDF
go.drugbank.com/drugs/DB05138ExperimentalAdPEDF is under development for the treatment of wet age-related macular degeneration (AMD). It has been shown to rapidly elevate the intraocular AdPEDF protein levels in the eye, inhibit abnormal blood vessel growth, and cause abnormal ...